Prosight Management, LP Graphite Bio, Inc. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.24 - $2.66 $31,613 - $37,540	14,113 Added 1.05%	1,351,939 $3.54 Million
Q3 2023 Nov 14, 2023	SELL	$2.18 - $2.77 $789,539 - $1 Million	-362,174 Reduced 21.3%	1,337,826 $3.32 Million
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $2.03 Million - $2.78 Million	823,334 Added 93.92%	1,700,000 $4.42 Million
Q1 2023 May 12, 2023	SELL	$1.85 - $3.21 $73,800 - $128,053	-39,892 Reduced 4.35%	876,666 $2.15 Million
Q4 2022 Feb 14, 2023	BUY	$2.82 - $3.59 $1.58 Million - $2.01 Million	560,113 Added 157.14%	916,558 $3.04 Million
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $1.01 Million - $1.51 Million	356,445 New	356,445 $1.13 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.